Dr. Cortes on Tyrosine Kinase Inhibitors in CML

Jorges E. Cortes, MD
Published: Saturday, Feb 29, 2020



Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, shares his experience with tyrosine kinase inhibitors (TKIs) as treatment of patients with chronic myeloid leukemia.

We need to use TKIs properly, Cortes emphasizes. He does not stay away from any of the TKIs when they are appropriate treatment for his patients. However, it is important to closely monitor patients on TKIs.

Patients should be monitored closely and not just for polymerase chain reaction, which have been emphasized a lot in the past. Cortes says physicians should monitor everything that is a part of the patient’s clinical context. If patients are managed properly, physicians can decrease the risks and make the best possible outcomes for patients.


Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, shares his experience with tyrosine kinase inhibitors (TKIs) as treatment of patients with chronic myeloid leukemia.

We need to use TKIs properly, Cortes emphasizes. He does not stay away from any of the TKIs when they are appropriate treatment for his patients. However, it is important to closely monitor patients on TKIs.

Patients should be monitored closely and not just for polymerase chain reaction, which have been emphasized a lot in the past. Cortes says physicians should monitor everything that is a part of the patient’s clinical context. If patients are managed properly, physicians can decrease the risks and make the best possible outcomes for patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x